Abstract:The liver produces endogenous glucose to support life during fasting. Counterregulatory hormones, including glucagon, catecholamines, and glucocorticoids, stimulate the expression of gluconeogenic enzymes in the liver, thus driving liver glucose production. In contrast, insulin suppresses hepatic gluconeogenesis, thereby restraining postprandial glucose levels. Hepatic gluconeogenesis aberrantly increases in type 2 diabetes due to an imbalance between insulin and counterregulatory hormone actions, contributing to hyperglycemia and glucose intolerance. N6-methyladenosine (m6A) RNA methylation has emerged as a critical paradigm shaping cell identities and functions. The Mettl3/Mettl14 complex catalyzes m6A on RNA and RNA-binding proteins bind to the m6A motifs and determine the fate of client mRNAs (splicing, trafficking, stability, and/or translation) . However, m6A RNA modification has not been explored in liver gluconeogenesis. Here, we identified Mettl14 as an important positive regulator of hepatic gluconeogenesis. Liver Mettl14 levels were increased in db/db mice and mice with high fat diet (HFD) -induced obesity. Hepatocyte-specific deletion of Mettl14 decreased hepatic glucose production and ameliorated HFD-induced glucose intolerance; conversely, liver-specific overexpression of Mettl14 increased liver glucose production and HFD-induced glucose intolerance. Of note, Mettl14 did not alter liver insulin actions under our experimental conditions. Remarkably, hepatic deficiency of Mettl14 profoundly blunted the ability of glucagon to stimulate gluconeogenesis in mice. Consistently, deletion of Mettl14 largely blocked glucagon-stimulated gluconeogenesis ex vivo in liver slices as well as in primary hepatocyte cultures. In contrast, overexpression of Mettl14 had the opposite effects. Collectively, these data unravel a previously unrecognized glucagon/Mettl14/gluconeogenesis axis that is involved in hyperglycemia and glucose intolerance in diabetes. Disclosure Q. Zheng: None. X. Zhong: None. D. Ren: None. L. Rui: None. Funding National Institutes of Health (RO1DK127568) , American Heart Association (831585)

N6-methyladenosine modification governs liver glycogenesis by stabilizing the glycogen synthase 2 mRNA

216-LB: Hepatocyte N6-Methyladenosine mRNA Modification in Hepatic Gluconeogenesis and Diabetes

Regulation Of Glucose Homeostasis And Lipid Metabolism By Ppp1r3g-Mediated Hepatic Glycogenesis

N 6 -Methyladenosine Modification-Mediated Mrna Metabolism is Essential for Human Pancreatic Lineage Specification and Islet Organogenesis

Mettl3-Mediated M6a Modification Plays a Role in Lipid Metabolism Disorders and Progressive Liver Damage in Mice by Regulating Lipid Metabolism-Related Gene Expression

Mettl3-mediated Mrna M6a Modification Controls Postnatal Liver Development by Modulating the Transcription Factor Hnf4a

Mettl14-Mediated M6a Modification Facilitates Liver Regeneration by Maintaining Endoplasmic Reticulum Homeostasis

The m 6 A reader IGF2BP2 regulates glycolytic metabolism and mediates histone lactylation to enhance hepatic stellate cell activation and liver fibrosis

Rna M6a Methylation Regulates Glycolysis of Beige Fat and Contributes to Systemic Metabolic Homeostasis

The M6a Reader IGF2BP2 Regulates Glycolytic Metabolism and Mediates Histone Lactylation to Enhance Hepatic Stellate Cell Activation and Liver Fibrosis

Longitudinal Epi-Transcriptome Profiling Reveals the Crucial Role of M6a in Prenatal Skeletal Muscle Development of Pigs

m6A mRNA Methylation Controls Functional Maturation in Neonatal Murine β-Cells

N6-methyladenosine modification-mediated mRNA metabolism is essential for human pancreatic lineage specification and islet organogenesis

M6a Regulates Neurogenesis and Neuronal Development by Modulating Histone Methyltransferase Ezh2

New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC

N6‐Methyladenosine Reader Protein YT521‐B Homology Domain‐Containing 2 Suppresses Liver Steatosis by Regulation of Mrna Stability of Lipogenic Genes

N6-Methyladenosine Modulates Nonsense-Mediated mRNA Decay in Human Glioblastoma

The m6A Methyltransferase METTL3 Ameliorates Methylglyoxal-Induced Impairment of Insulin Secretion in Pancreatic β Cells by Regulating MafA Expression

m6A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity

Mettl3-m6A-YTHDF1 axis promotion of mitochondrial dysfunction in metabolic dysfunction-associated steatotic liver disease

Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma